InhibOx appoints Paul Davie to lead Commercial Growth

Oxford, UK - August 2009

InhibOx today appointed Paul Davie to drive the next phase of commercial development of the company.

Paul, who studied Chemistry at Oxford University and then the Max-Planck-Gessellschaft in Berlin, has a 25-year track record of success in senior roles in the computer-aided computational chemistry sector. He spent eight years at Chemical Design Ltd before joining Oxford Molecular where he built and managed their commercial operations across Europe. He went on to serve as European General Manager for Accelrys and Chief Operating Officer at Inforsense. He subsequently became the founding CEO at Secerno, the successful database security firm, before returning to the life sciences sector.

Paul will be acting as a consultant to the company, working alongside CEO Dr Paul Finn. Dr Finn said “We are delighted to have such an experienced industry professional on the InhibOx team, to work with us to make the most in the huge growth in interest in virtual screening technology and services.”

Paul Davie commented, “InhibOx is uniquely positioned with leading proprietary technology and the best scientific team in the industry. The company is set up to succeed.”